Prostate cancer screening in the PSA era is controversial and the most appropriate measures for diagnosis are widely debated. Vickers and colleagues recently suggested that using PSA velocity in screening offers little benefit compared with traditional markers; however, elimination of this test from practice or guidelines may be premature.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stattin, P. et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J. Natl Cancer Inst. 102, 950–958 (2010).
Vickers, A. J., Till, C., Tangen, C. M., Lilja, H. & Thompson, I. M. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J. Natl Cancer Inst. 103, 462–469 (2011).
D'Amico, A. V., Chen, M.-H., Roehl, K. A. & Catalona, W. J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 351, 125–135 (2004).
Carter, H. B. et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J. Natl Cancer Inst. 98, 1521–1527 (2006).
NCCN Clinical Practice Guidelines in Oncology: prostate cancer early detection. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection (2010).
Greene, K. L. et al. Prostate specific antigen best practice statement: 2009 update. J. Urol. 182, 2232–2241 (2009).
Thompson, I. M. et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 98, 529–534 (2006).
Mitka, M. Experts debate utility of PSA velocity as a criterion for prostate biopsy. JAMA 305, 1522 (2011).
Sun, L. et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in med aged <50 years. BJU Int. 99, 753–757 (2007).
Shariat, S., Karakiewicz, P., Marguilis, V. & Kattan, M. W. Inventory of prostate cancer predictive tools. Curr. Opin. Urol. 18, 279–296 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Borofsky, M., Makarov, D. PSA velocity in prostate cancer screening—the debate continues. Nat Rev Urol 8, 413–414 (2011). https://doi.org/10.1038/nrurol.2011.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.87
